Search the Newsreel

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

Winking Studios Revenue Climbs as North American and AI Expansion Accelerates

CuriosityStream Inc. (CURI) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for CuriosityStream Inc. (CURI) stock, showing its current price of $3.55, a decrease of 11.03%. It also includes information on analyst ratings, which are currently unavailable, and states that earnings information for the company is not yet …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS

PlaySide Studios Counts Down To FY26 Results As Its Game Of Thrones Title Slips Into 2027

Winking Studios Boosts Revenue as It Accelerates North American and AI Investments

Earnings Flash (WKS.L) Winking Studios Reports H1 Revenue $23.5M

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johnson) * "At the same time, we continued …

Arcadia Biosciences earnings missed by $1.53, revenue fell short of estimates

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …

Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On?

Jade Biosciences (JBIO) recently released its Q2 2026 results, reporting a net loss of $55.77 million. Despite strong year-to-date share price returns of 63.91% and a 1-year total shareholder return of 216.64%, the stock's 90-day return declined, and it trades well below the average …

H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55

H.C. Wainwright has reiterated its Buy rating for Jade Biosciences (JBIO.US), keeping the target price at $55. This indicates continued confidence in the company's performance and future prospects from the analyst firm.

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …

Caribou Biosciences (NASDAQ:CRBU) Releases Earnings Results, Beats Expectations By $0.08 EPS

Caribou Biosciences (NASDAQ:CRBU) reported a quarterly loss of $0.24 per share, surpassing analyst expectations by $0.08, though revenue of $1.50 million fell short of estimates. Following the announcement, shares declined by 5.3% to $1.61. Despite substantial losses and a negative net margin, institutional investors …

Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair of the Board - Bob Duggan Need a …

Navios Maritime Partners (NMM) Q2 2024 Earnings Report - Results, Call & Slides

This article provides the Q2 2024 earnings report for Navios Maritime Partners (NMM), detailing their actual EPS of $3.06 which beat the consensus of $2.84, and actual revenue of $342.16M, exceeding the expected $312.39M. It includes earnings announcement details, a link to the earnings …

NovaBridge Biosciences to report H1FY26 results on Aug 20

NovaBridge Biosciences (NASDAQ: NBP) will hold a webcast on August 20, 2026, to discuss its financial results for the first half ended June 30, 2026, and provide a corporate update. The company, focused on oncology and ophthalmology programs, will host the webcast at 9:00 …

CURI | CuriosityStream Inc. Class A Financials - Revenue Breakdown

Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for …

Assembly Biosciences earnings beat by $0.53, revenue topped estimates

Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com

This article reports that Ensysce Biosciences Inc. filed a Form 8K on August 13. The company's stock symbol is ENSC, which saw a 14.75% increase. The article provides only this financial filing information without further details on the content of the Form 8K.

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Satellos Bioscience: Q2 Earnings Snapshot

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

NovaBridge webcast to cover oncology and ophthalmology programs

NovaBridge Biosciences (Nasdaq: NBP) announced it will host a webcast on Thursday, August 20, 2026, at 9:00 AM ET / 9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026. The company is …

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

NovaBridge Biosciences announced it will hold a webcast on Thursday, August 20, 2026, to discuss its first half 2026 financial results and corporate progress. The company, a global biotechnology firm focused on oncology and ophthalmology, will host the webcast at 9:00 AM ET/9:00 PM …

Satellos Q2 loss widens to $11.7M, EPS misses estimates

Satellos Bioscience reported a Q2 2026 net loss of $11.7 million, or $0.56 per share, missing analyst estimates due to significantly increased R&D spending on its Phase 2 DMD clinical trials. Despite the widening loss, the company's cash reserves rose to $61.8 million, providing …

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

Satellos Bioscience Inc. announced its Q2 2026 financial results, reporting a strong cash position of $61.8 million and progress in its clinical trials for SAT-3247, a drug candidate for Duchenne muscular dystrophy (DMD). The company highlighted favorable safety data from the TRAILHEAD adult DMD …

Satellos reports stable strength in four-adult Duchenne study

Satellos reported its second quarter 2026 financial results, including a net loss of $11.7 million, and provided updates on its clinical progress for SAT-3247 in Duchenne muscular dystrophy (DMD). The company highlighted stable strength and reduced muscle fat in a Phase 2 adult DMD …